

Subscribe to
Bioshares
\$550/
24 issues

More details can be found
on the back page

Companies covered: AVR, CHM, CUV,
EBR, OVN, PXS, SOM, VTI

Bioshares

14 February 2022
Edition 911

*Delivering independent investment research to investors on Australian
biotech, pharma and healthcare companies*

Extract from Bioshares –

Pharmaxis Update

On a recent investor call, Pharmaxis (PXS: \$0.097) CEO Gary Phillips said that the company's Phase I/IIa trial in patients with myelofibrosis is on target to complete recruitment by mid-year with results still due at the end of the year.

Phillips said that the drug candidate, PXS-5505, is performing very well at this stage, inhibiting 90% of the target enzyme with a good safety profile being well tolerated by patients. The study is seeking to recruit 24 patients with the results likely to be a key share price driver for the stock.

Late last year it was announced that an IND filed by the University of Rochester Medical Center was accepted by the FDA with that group to trial the drug in patients with liver cancer. It will be an interesting and meaningful study, with PXS-5505 to be given to patients as a first line therapy. Patients will also be receiving a PD-L1 inhibitor and a VEGF inhibitor. Of primary interest will be to see if the Pharmaxis drug compound can disrupt the tumour cross-linking to allow these new therapies to take better effect inside the tumour.

Researchers from the University of Rochester have undertaken preclinical studies with PXS-5505 that were presented at a scientific meeting in August last year. Phillips said that if the compound can be shown to work in liver cancer then there is very high chance of working in other tumours, presumably in particularly highly stromal (fibrotic) tumours.

Late last year Pharmaxis raised \$9.8 million (at \$0.105 per share). Karst Peak Capital has increased its stake from 11.3% to 12.3%. One of the reasons for the raise was due to an expected decrease in Bronchitol sales with cystic fibrosis patients staying at home due to the pandemic.

Pharmaxis is capitalised at \$51 million with \$21 million in cash at the end of last year. For the December quarter, cash receipts totalled \$3.8 million with an operating cash outflow of \$3.7 million.

Bioshares Recommendation: **Speculative Buy Class A**

Bioshares

| | Bioshares Portfolio |
|-----------------------------|---------------------|
| Year 1 (May '01 - May '02) | 21.2% |
| Year 2 (May '02 - May '03) | -9.4% |
| Year 3 (May '03 - May '04) | 70.6% |
| Year 4 (May '04 - May '05) | -16.3% |
| Year 5 (May '05 - May '06) | 77.8% |
| Year 6 (May '06 - May '07) | 17.4% |
| Year 7 (May '07 - May '08) | -35.8% |
| Year 8 (May '08 - May '09) | -7.4% |
| Year 9 (May '09 - May '10) | 50.2% |
| Year 10 (May '10 - May '11) | 45.4% |
| Year 11 (May '11 - May '12) | -18.0% |
| Year 12 (May '12 - May '13) | 3.1% |
| Year 13 (May '13 - May '14) | 26.6% |
| Year 14 (May '14 - May '15) | 23.0% |
| Year 15 (May '15 - May '16) | 33.0% |
| Year 16 (May '16 - May '17) | 16.8% |
| Year 17 (May '17 - May '18) | -7.1% |
| Year 18 (May '18 - May '19) | -2.3% |
| Year 19 (May '19 - May '20) | 39.5% |
| Year 20 (May '20 - May '21) | 86.8% |
| Year 21 (May '21 - Current) | 0.5% |
| Cumulative Gain | 1944% |
| Av. Annual gain (20 yrs) | 20.7% |

Bioshares is published by Blake Industry & Market Analysis Pty Ltd.
ACN 085 334 292
PO Box 193
Richmond Vic 3121
AFS Licence No. 258032

Mark Pachacz - Editor/Analyst
Email: mark[at]bioshares.com.au
Ph: 0403 850 425

Edition Number 911 (14 February 2022)

Copyright 2021 Blake Industry and Market Analysis Pty Ltd. ALL RIGHTS RESERVED.
Secondary electronic transmission, photocopying, reproduction or quotation is strictly prohibited without written consent of the publisher.

How Bioshares Rates Stocks

For the purpose of valuation, Bioshares divides biotech stocks into two categories. The first group are stocks with existing positive cash flows or close to producing positive cash flows. The second group are stocks without near term positive cash flows, history of losses, or at early stages of commercialisation. In this second group, which are essentially speculative propositions, Bioshares grades them according to relative risk within that group, to better reflect the very large spread of risk within those stocks. For both groups, the rating “Take Some Profits” means that investors may re-weight their holding by selling between 25%-75% of a stock.

Group A

Stocks with existing positive cash flows or close to producing positive cash flows

- Buy** CMP is 20% < Fair Value
- Accumulate** CMP is 10% < Fair Value
- Hold** Value = CMP
- Lighten** CMP is 10% > Fair Value
- Sell** CMP is 20% > Fair Value
(CMP–Current Market Price)

Group B

Stocks without near term positive cash flows, history of losses, or at early stages of commercialisation.

Speculative Buy – Class A

These stocks will have more than one technology, product or investment in development, with perhaps those same technologies offering multiple opportunities. These features, coupled to the presence of alliances, partnerships and scientific advisory boards, indicate the stock is relative less risky than other biotech stocks.

Speculative Buy – Class B

These stocks may have more than one product or opportunity, and may even be close to market. However, they are likely to be lacking in several key areas. For example, their cash position is weak, or management or board may need strengthening.

Speculative Buy – Class C

These stocks generally have one product in development and lack many external validation features.

Speculative Hold – Class A or B or C

Sell

Corporate Subscribers: Cogstate, Opthea, ResApp Health, Pharmaxis, Dimerix, Adalta, Actinogen Medical, Patrys, Antisense Therapeutics, Imugene, Exopharm, Immutep, Invex Therapeutics, Anteris Technologies, Chimeric Therapeutics, Neuren Pharmaceuticals, Neurotech International, Aroa Biosurgery

Disclaimer:

Information contained in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein expressed represent the current judgement of the publisher and are subject to change. Blake Industry and Market Analysis Pty Ltd (BIMA) and any of their associates, officers or staff may have interests in securities referred to herein (Corporations Law s.849). Details contained herein have been prepared for general circulation and do not have regard to any person’s or company’s investment objectives, financial situation and particular needs. Accordingly, no recipients should rely on any recommendation (whether express or implied) contained in this document without consulting their investment adviser (Corporations Law s.851). The persons involved in or responsible for the preparation and publication of this report believe the information herein is accurate but no warranty of accuracy is given and persons seeking to rely on information provided herein should make their own independent enquiries. Details contained herein have been issued on the basis they are only for the particular person or company to whom they have been provided by Blake Industry and Market Analysis Pty Ltd. The Directors and/or associates declare interests in the following ASX Healthcare and Biotechnology sector securities: Analyst MP: ACR,CGS, CYC, DXB, IMM, OPT,CUV,MX1, NEU, PAB, PXS,RNO,SOM. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 are not disclosed.

Subscription Rates (inc. GST)

24 issues per year (electronic distribution): **\$550**

For multiple email distributions within \$900 2-3 email addresses
 the same business cost centre, our \$1200 4-5 email addresses
 pricing structure is as follows: \$1500 6-10 email addresses

To subscribe, post/email this subscription form to:

Bioshares
PO Box 193 Richmond VIC 3121
info@bioshares.com.au

I enclose a cheque for \$ _____ made payable to **Blake Industry & Market Analysis Pty Ltd**, or

Please charge my credit card \$ _____ MasterCard Visa

Card Number

Signature _____ Expiry date _____

Subscriber details

Name _____

Organisation _____

Ph () _____

Emails _____

The information provided in Bioshares, including general investment advice, is provided only for receipt and use in Australia and New Zealand, for subscribers to Bioshares, who are Australian or New Zealand citizens or commercial entities.